Long-term (2–5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis

Abstract Several previously published trials comparing Zotarolimus Eluting Stents (ZES) with Sirolimus Eluting Stents (SES), Paclitaxel Eluting Stents (PES) or Everolimus Eluting Stents (EES) at a follow up period of 1 year, were continually being followed up in order to assess the long-term outcome...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pravesh Kumar Bundhun, Akash Bhurtu, Manish Pursun, Mohammad Zafooruddin Sani Soogund, Abhishek Rishikesh Teeluck, Wei-Qiang Huang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/eb4f01da6094445ea7f0f662ef0f90f9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eb4f01da6094445ea7f0f662ef0f90f9
record_format	dspace
spelling	oai:doaj.org-article:eb4f01da6094445ea7f0f662ef0f90f92021-12-02T15:05:31ZLong-term (2–5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis10.1038/s41598-017-06705-y2045-2322https://doaj.org/article/eb4f01da6094445ea7f0f662ef0f90f92017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-06705-yhttps://doaj.org/toc/2045-2322Abstract Several previously published trials comparing Zotarolimus Eluting Stents (ZES) with Sirolimus Eluting Stents (SES), Paclitaxel Eluting Stents (PES) or Everolimus Eluting Stents (EES) at a follow up period of 1 year, were continually being followed up in order to assess the long-term outcomes. In this meta-analysis, we aimed to compare the long-term (2–5 years) adverse clinical outcomes which were associated with ZES versus SES, PES and EES following Percutaneous Coronary Intervention (PCI). Risk Ratios (RR) with 95% Confidence Intervals (CIs) were generated and the analysis was carried out by the RevMan 5.3 software. In this analysis with a total number of 17,606 participants, ZES and EES were associated with similar adverse outcomes including Stent Thrombosis (ST), myocardial infarction (MI), major adverse cardiac events and repeated revascularization. When ZES were compared with SES and PES during the long-term, MI and definite or probable ST were significantly lower with ZES, with RR: 1.35, 95% CI: 1.17–1.56; P = 0.0001 and RR: 1.91, 95% CI: 1.33–2.75; P = 0.0004 respectively whereas the other adverse outcomes were similarly manifested. Future research should be able to confirm this hypothesis.Pravesh Kumar BundhunAkash BhurtuManish PursunMohammad Zafooruddin Sani SoogundAbhishek Rishikesh TeeluckWei-Qiang HuangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-18 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Pravesh Kumar Bundhun Akash Bhurtu Manish Pursun Mohammad Zafooruddin Sani Soogund Abhishek Rishikesh Teeluck Wei-Qiang Huang Long-term (2–5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis
description	Abstract Several previously published trials comparing Zotarolimus Eluting Stents (ZES) with Sirolimus Eluting Stents (SES), Paclitaxel Eluting Stents (PES) or Everolimus Eluting Stents (EES) at a follow up period of 1 year, were continually being followed up in order to assess the long-term outcomes. In this meta-analysis, we aimed to compare the long-term (2–5 years) adverse clinical outcomes which were associated with ZES versus SES, PES and EES following Percutaneous Coronary Intervention (PCI). Risk Ratios (RR) with 95% Confidence Intervals (CIs) were generated and the analysis was carried out by the RevMan 5.3 software. In this analysis with a total number of 17,606 participants, ZES and EES were associated with similar adverse outcomes including Stent Thrombosis (ST), myocardial infarction (MI), major adverse cardiac events and repeated revascularization. When ZES were compared with SES and PES during the long-term, MI and definite or probable ST were significantly lower with ZES, with RR: 1.35, 95% CI: 1.17–1.56; P = 0.0001 and RR: 1.91, 95% CI: 1.33–2.75; P = 0.0004 respectively whereas the other adverse outcomes were similarly manifested. Future research should be able to confirm this hypothesis.
format	article
author	Pravesh Kumar Bundhun Akash Bhurtu Manish Pursun Mohammad Zafooruddin Sani Soogund Abhishek Rishikesh Teeluck Wei-Qiang Huang
author_facet	Pravesh Kumar Bundhun Akash Bhurtu Manish Pursun Mohammad Zafooruddin Sani Soogund Abhishek Rishikesh Teeluck Wei-Qiang Huang
author_sort	Pravesh Kumar Bundhun
title	Long-term (2–5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis
title_short	Long-term (2–5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis
title_full	Long-term (2–5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis
title_fullStr	Long-term (2–5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis
title_full_unstemmed	Long-term (2–5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis
title_sort	long-term (2–5 years) adverse clinical outcomes associated with zes versus ses, pes and ees: a meta-analysis
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/eb4f01da6094445ea7f0f662ef0f90f9
work_keys_str_mv	AT praveshkumarbundhun longterm25yearsadverseclinicaloutcomesassociatedwithzesversussespesandeesametaanalysis AT akashbhurtu longterm25yearsadverseclinicaloutcomesassociatedwithzesversussespesandeesametaanalysis AT manishpursun longterm25yearsadverseclinicaloutcomesassociatedwithzesversussespesandeesametaanalysis AT mohammadzafooruddinsanisoogund longterm25yearsadverseclinicaloutcomesassociatedwithzesversussespesandeesametaanalysis AT abhishekrishikeshteeluck longterm25yearsadverseclinicaloutcomesassociatedwithzesversussespesandeesametaanalysis AT weiqianghuang longterm25yearsadverseclinicaloutcomesassociatedwithzesversussespesandeesametaanalysis
_version_	1718388801875738624

Long-term (2–5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis

Ejemplares similares